Underestimated impact of novel psychoactive substances: laboratory confirmation of recreational drug toxicity in Oslo, Norway

References

• Dines AM, Wood DM, Yates C, et al. Acute recreational drug and new psychoactive substance toxicity in Europe: 12 months data collection from the European Drug Emergencies Network (Euro-DEN). Clin Toxicol. 2015;53:893–900.
   PubMed Web of Science ®Google Scholar
• Lund C, Drottning P, Stiksrud B, et al. A one-year observational study of all hospitalized acute poisonings in Oslo: complications, treatment and sequelae. Scand J Trauma Resusc Emerg Med. 2012;20:49.
   PubMed Web of Science ®Google Scholar
• Vallersnes OM, Jacobsen D, Ekeberg O, et al. Patients presenting with acute poisoning to an outpatient emergency clinic: a one-year observational study in Oslo, Norway. BMC Emerg Med. 2015;15:18.
   PubMed Web of Science ®Google Scholar
• European monitoring centre for drugs and drug addiction. European Drug Report 2015. Trends and developments. Lisbon, Portugal: EMCDDA; 2015.
   Google Scholar
• European monitoring centre for drugs and drug addiction. European Drug Report 2016. Trends and developments. Lisbon, Portugal: EMCDDA; 2016.
   Google Scholar
• Heyerdahl F, Hovda KE, Giraudon I, et al. Current European data collection on emergency department presentations with acute recreational drug toxicity: gaps and national variations. Clin Toxicol. 2014;52:1005–1012.
   PubMed Web of Science ®Google Scholar
• Peters FT, Meyer MF, Analytical techniques for the detection of novel psychoactive substances and their metabolites. In: Dargan PI, Wood DM, editors. Novel psychoactive substances: classification, pharmacology and toxicology. London, UK: Academic Press; 2013. p. 131–157.
   Google Scholar
• Heyerdahl F, Hovda KE, Bjornaas MA, et al. Clinical assessment compared to laboratory screening in acutely poisoned patients. Hum Exp Toxicol. 2008;27:73–79.
   PubMed Web of Science ®Google Scholar
• Mordal J, Holm B, Morland J, et al. Recent substance intake among patients admitted to acute psychiatric wards: physician's assessment and on-site urine testing compared with comprehensive laboratory analyses. J Clin Psychopharmacol. 2010;30:455–459.
   PubMed Web of Science ®Google Scholar
• Bjornaas MA, Hovda KE, Mikalsen H, et al. Clinical vs. laboratory identification of drugs of abuse in patients admitted for acute poisoning. Clin Toxicol. 2006;44:127–134.
   Web of Science ®Google Scholar
• Wood DM, Heyerdahl F, Yates CB, et al. The European Drug Emergencies Network (Euro-DEN). Clin Toxicol. 2014;52:239–241.
   PubMed Web of Science ®Google Scholar
• Oiestad EL, Johansen U, Oiestad AM, et al. Drug screening of whole blood by ultra-performance liquid chromatography-tandem mass spectrometry. J Anal Toxicol. 2011;35:280–293.
   PubMed Web of Science ®Google Scholar
• Karinen R, Johnsen L, Andresen W, et al. Stability study of fifteen synthetic cannabinoids of aminoalkylindole type in whole blood, stored in Vacutainer® evacuated glass tubes. J Forensic Toxicol Pharmacol 2013;2:1.
   Google Scholar
• Oiestad EL, Johansen U, Christophersen AS, et al. Screening of synthetic cannabinoids in preserved oral fluid by UPLC-MS/MS. Bioanalysis. 2013;5:2257–2268.
   PubMed Web of Science ®Google Scholar
• Lund HM, Oiestad EL, Gjerde H, et al. Drugs of abuse in oral fluid collected by two different sample kits-stability testing and validation using ultra performance tandem mass spectrometry analysis. J Chromatogr B Analyt Technol Biomed Life Sci. 2011;879:3367–3377.
   PubMed Web of Science ®Google Scholar
• Oiestad EL, Johansen U, Christophersen AS. Drug screening of preserved oral fluid by liquid chromatography-tandem mass spectrometry. Clin Chem. 2007;53:300–309.
   PubMed Web of Science ®Google Scholar
• Kristoffersen L, Smith-Kielland A. An automated alcohol dehydrogenase method for ethanol quantification in urine and whole blood. J Anal Toxicol. 2005;29:387–389.
   PubMed Web of Science ®Google Scholar
• Dahl SR, Olsen KM, Strand DH. Determination of γ-hydroxybutyrate (GHB), β-hydroxybutyrate (BHB), pregabalin, 1,4-butane-diol (1,4BD) and γ-butyrolactone (GBL) in whole blood and urine samples by UPLC-MSMS. J Chromatogr B Analyt Technol Biomed Life Sci. 2012;885-886:37–42.
   PubMed Web of Science ®Google Scholar
• Sergeant ESG. Epitools epidemiological calculators [Internet]. Australia: AusVet Animal Health Services and Australian Biosecurity Cooperative Research Centre for Emerging Infectious Disease; 2016 [cited 2016 Jan 8]. Available from: http://epitools.ausvet.com.au/
   Google Scholar
• Blanckaert P, van Amsterdam J, Brunt T, et al. 4-Methyl-amfetamine: a health threat for recreational amfetamine users. J Psychopharmacol (Oxford). 2013;27:817–822.
   PubMed Web of Science ®Google Scholar
• European Monitoring Centre for Drugs and Drug Addiction. 4-Methylamfetamine (4-MA): report on the risk assessment of 4-methylamfetamine in the framework of the Council Decision on new psychoactive substances. Luxembourg: EMCDDA; 2014.
   Google Scholar
• Cody JT. Detection of D,L-amfetamine, D,L-methamfetamine, and illicit amfetamine analogs using diagnostic products corporation's amfetamine and methamfetamine radioimmunoassay. J Anal Toxicol. 1990;14:321–324.
   PubMed Web of Science ®Google Scholar
• Rickli A, Kopf S, Hoener MC, et al. Pharmacological profile of novel psychoactive benzofurans. Br J Pharmacol. 2015;172:3412–3425.
   PubMed Web of Science ®Google Scholar
• Karila L, Billieux J, Benyamina A, et al. The effects and risks associated to mephedrone and methylone in humans: a review of the preliminary evidences. Brain Res Bull. 2016;126:61–67.
   PubMed Web of Science ®Google Scholar
• Obafemi AI, Kleinschmidt K, Goto C, et al. Cluster of acute toxicity from ingestion of synthetic cannabinoid-laced brownies. J Med Toxicol. 2015;11:426–429.
   PubMed Web of Science ®Google Scholar
• Tuv SS, Krabseth H, Karinen R, et al. Prevalence of synthetic cannabinoids in blood samples from Norwegian drivers suspected of impaired driving during a seven weeks period. Accid Anal Prev. 2014;62:26–31.
   PubMed Web of Science ®Google Scholar
• Hermanns-Clausen M, Kithinji J, Spehl M, et al. Adverse effects after the use of JWH-210 – a case series from the EU Spice II plus project. Drug Test Anal. 2016;8:1030–1038.
   PubMed Web of Science ®Google Scholar
• Dos Santos RG, Balthazar FM, Bouso JC, et al. The current state of research on ayahuasca: a systematic review of human studies assessing psychiatric symptoms, neuropsychological functioning, and neuroimaging. J Psychopharmacol. 2016;30:1230–1247.
   PubMed Web of Science ®Google Scholar
• Carbonaro TM, Gatch MB. Neuropharmacology of N,N-dimethyltryptamine. Brain Res Bull. 2016;126:74–88.
   PubMed Web of Science ®Google Scholar
• Lund C, Vallersnes OM, Jacobsen D, et al. Outpatient treatment of acute poisonings in Oslo: poisoning pattern, factors associated with hospitalization, and mortality. Scand J Trauma Resusc Emerg Med. 2012;20:1.
   PubMed Web of Science ®Google Scholar
• Euro-DEN Research Group. Final Report of the European Drug Emergencies Network (Euro‐DEN). London, UK; 2015.
   Google Scholar
• Liakoni E, Dolder PC, Rentsch KM, et al. Presentations due to acute toxicity of psychoactive substances in an urban emergency department in Switzerland: a case series. BMC Pharmacol Toxicol. 2016;17:25.
   PubMed Web of Science ®Google Scholar
• Liakoni E, Dolder PC, Rentsch K, et al. Acute health problems due to recreational drug use in patients presenting to an urban emergency department in Switzerland. Swiss Med Wkly. 2015;145:w14166.
   PubMed Web of Science ®Google Scholar
• Gjersing L, Jonassen KV, Biong S, et al. Diversity in causes and characteristics of drug-induced deaths in an urban setting. Scand J Public Health. 2013;41:119–125.
   PubMed Web of Science ®Google Scholar
• Steentoft A, Teige B, Holmgren P, et al. Fatal poisonings in young drug addicts in the Nordic countries: a comparison between 1984–1985 and 1991. Forensic Sci Int. 1996;78:29–37.
   PubMed Web of Science ®Google Scholar
• Jonsson A, Holmgren P, Ahlner J. Fatal intoxications in a Swedish forensic autopsy material during 1992–2002. Forensic Sci Int. 2004;143:53–59.
   PubMed Web of Science ®Google Scholar
• Schep LJ, Knudsen K, Slaughter RJ, et al. The clinical toxicology of gamma-hydroxybutyrate, gamma-butyrolactone and 1,4-butanediol. Clin Toxicol. 2012;50:458–470.
   PubMed Web of Science ®Google Scholar
• Bramness JG, Reid MJ, Solvik KF, et al. Recent trends in the availability and use of amfetamine and methamfetamine in Norway. Forensic Sci Int. 2015;246:92–97.
   PubMed Web of Science ®Google Scholar
• Paterson S, Cordero R. Comparison of the various opiate alkaloid contaminants and their metabolites found in illicit heroin with 6-monoacetyl morphine as indicators of heroin ingestion. J Anal Toxicol. 2006;30:267–273.
   PubMed Web of Science ®Google Scholar